Randomized phase II studies of VIRACEPTTM, an HIV protease inhibitor, given as monotherapy and in combination with stavudine (d4T): J. Peterkin1, S. Chapman1, M. Conant2, J. Gathe, Jr.3, P. Hawley4, M. Markowitz5. 1Agouron Pharmaceuticals, Inc., La Jolla, CA; 2Conant Medical Group, San Francisco, CA; 3Montrose Clinic, Houston, TX; 4Whitman-Walker Clinic, Inc., Washington, D.C.; Aaron 5Diamond AIDS Research Center, N.Y.